AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04016740
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative infusion
Trial: NCT04016740
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative inhaled as needed
Trial: NCT04016740
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Post-operative infusion
Trial: NCT04016740
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-operative infusion
Trial: NCT03312751
Drug: Emapalumab
RxNorm normalized name: Emapalumab
DrugBank: Emapalumab (DB14724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emapalumab will be administered by intravenous infusion, twice weekly.
Trial: NCT01155479
Drug: Preladenant 2 mg tablet
RxNorm normalized name: Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preladenant 2 mg oral tablet taken twice daily
Trial: NCT01155479
Drug: Preladenant 5 mg tablet
RxNorm normalized name: Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preladenant 5 mg oral tablet taken twice daily
Trial: NCT01155479
Drug: Preladenant 10 mg tablet
RxNorm normalized name: Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preladenant 10 mg oral tablet taken twice daily
Trial: NCT01155479
Drug: Rasagiline 1 mg capsule
RxNorm normalized name: rasagiline 1 MG
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rasagiline 1 mg oral capsule taken once daily
Trial: NCT01155479
Drug: Placebo for Rasagiline 1 mg capsule
RxNorm normalized name: rasagiline 1 MG
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo for rasagiline 1 mg oral capsule taken once daily
Trial: NCT01155479
Drug: Placebo for Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
Trial: NCT01192243
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg qd po d3-16
Trial: NCT01192243
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg/m2 venous infusion,D1,q3w
Trial: NCT01192243
Drug: Cisplatin or carboplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin:75mg/m2, venous infusion,D1,q3w or Carboplatin: AUC 5, venous infusion, D1,q3w
Trial: NCT00218101
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04166773
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04072822
Drug: Anakinra and Zinc
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra is indicated for reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis. It has been previously studied in AH. Zinc is a nutritional supplement. Zinc supplementation reverses the clinical signs of zinc deficiency in participants with alcoholic liver disease.
Trial: NCT04072822
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone is indicated for numerous conditions including inflammatory disease. Corticosteroids, such as prednisolone, are considered standard of care in alcoholic liver disease.
Trial: NCT04175847
Drug: RC88
RxNorm normalized name: RC88
DrugBank: RC88 (DB18697)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I:Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.~Phase IIa indication exploration
Trial: NCT01409161
Drug: Arsenic Trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01409161
Drug: Gemtuzumab Ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT03477929
Drug: Ganirelix Acetate
RxNorm normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
Trial: NCT03477929
Drug: Cetrorelix Acetate
RxNorm normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
Trial: NCT04423029
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT00287170
Drug: Delayed Release 6MP or Calcitriol vs. Purinethol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03342300
Drug: pirarubicin
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Another effort has been made to improve the toxicity profile of conventional anthracyclines is the development of novel anthracycline analogs,such as pirarubicin.
Trial: NCT04596462
Drug: 68Ga-FAPI
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of SAPHO by PET/CT.
Trial: NCT00000138
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03706274
Drug: CX-188
RxNorm normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CX-188
Trial: NCT00550420
Drug: Rosiglitazone XR
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: experimental drug
Trial: NCT02252536
Drug: gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day
Trial: NCT00789750
Drug: Colesevelam
RxNorm normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam 625 mg tablets
Trial: NCT00789750
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg or 45 mg pioglitazone therapy
Trial: NCT00962390
Drug: S-equol
RxNorm normalized name: S-equol
DrugBank: Equol (DB11674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg S-equol 50mg S-equol, \& 150mg S-equol
Trial: NCT00686270
Drug: apricitabine
RxNorm normalized name: Apricitabine
DrugBank: Apricitabine (DB12855)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.
Trial: NCT04503551
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Will be administered as per the schedule described in individual arm.
Trial: NCT04503551
Drug: Intravitreal Ranibizumab 0.5 mg Injection
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Will be administered as per the schedule described in individual arm.
Trial: NCT00422773
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
Trial: NCT00161330
Drug: oral amoxicilline/clavulanic acid
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00161330
Drug: iv ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03199339
Drug: TBA-7371
RxNorm normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
Trial: NCT00088998
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00184574
Drug: biphasic insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00184574
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02633852
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01271790
Drug: Tegobuvir (GS-9190)
RxNorm normalized name: Tegobuvir
DrugBank: Tegobuvir (DB11852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegobuvir (GS-9190) capsule, 30 mg BID
Trial: NCT01271790
Drug: GS-9451
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9451 tablet, 200 mg once daily (QD)
Trial: NCT01271790
Drug: GS-9451
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9451 tablet, 200 mg QD
Trial: NCT00720473
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine with dosage range from 25 mg to 200 mg per day.
Trial: NCT01271790
Drug: Tegobuvir placebo
DrugBank: Tegobuvir (DB11852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching Tegobuvir (GS-9190) capsule BID
Trial: NCT01856283
Drug: Nilotinib 300mg BID
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib
Trial: NCT03538522
Drug: N-831(Traneurocin) 10 mg QD
RxNorm normalized name: tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 10 mg capsule of NA-831 QD for 24 weeks
Trial: NCT03538522
Drug: NA-831 (Traneurocin) 20 mg QD
RxNorm normalized name: fosinopril sodium 20 MG
DrugBank: Fosinopril (DB00492)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 20 mg capsule of NA-831 QD for 24 weeks
Trial: NCT03538522
Drug: NA-831 (Traneurocin) 40 mg QD
RxNorm normalized name: fosinopril sodium 40 MG
DrugBank: Fosinopril (DB00492)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 40 mg capsule of NA-831 QD or for 24 weeks
Trial: NCT03319901
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.~By inhibiting Bcl-2, venetoclax promotes cancer cell death.
Trial: NCT00670267
Drug: nadolol
RxNorm normalized name: Nadolol
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
Trial: NCT01495169
Drug: iloperidone (oral tablet)
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)
Trial: NCT00078312
Drug: CEP-10953 (Armodafinil)
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Armodafinil (po) 100 to 250 mg/day up to 12 months
Trial: NCT00006096
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01339858
Drug: N-Acetyl Cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose
Trial: NCT00063596
Drug: Vitamin A supplementation
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03202186
Drug: Progesterone oral capsule
RxNorm normalized name: progesterone Oral Capsule
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capsule treatment
Trial: NCT04099771
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine infusion
Trial: NCT02820935
Drug: CC-220
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02820935
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02820935
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01178112
Drug: Trientine
RxNorm normalized name: Trientine
DrugBank: Triethylenetetramine (DB06824)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.
Trial: NCT01178112
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.
Trial: NCT01198379
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin 100 mg qd for 3 years
Trial: NCT00413478
Drug: 5-Azacytidine
RxNorm normalized name: 5-azacytidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose level: 75mg/m\^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
Trial: NCT01178112
Drug: Carboplatin MTD
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Maximum tolerated dose found in MTD Dose Escalation Group
Trial: NCT02748616
Drug: Ursodiol
RxNorm normalized name: Ursodiol
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will begin to take 300 mg Ursodiol 2 (two) weeks after Visit #1 for a total of 8 (eight) weeks.
Trial: NCT02039817
Drug: IDN-6556
RxNorm normalized name: IDN-7314
DrugBank: IDN-7314 (DB18073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00106379
Drug: Truvada (tenofovir DF + emtricitabine)
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00106379
Drug: Emtriva (emtricitabine)
RxNorm normalized name: emtricitabine Oral Capsule [Emtriva]
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00106379
Drug: Viread (tenofovir DF)
RxNorm normalized name: tenofovir disoproxil Oral Tablet [Viread]
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01640093
Drug: Abiraterone acetate, 250 mg (uncoated, current commercial tablet)
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
Trial: NCT01640093
Drug: Abiraterone acetate, 500 mg (coated, reformulated tablet)
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
Trial: NCT03332797
Drug: GDC-9545
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-9545 will be administered orally, once daily, on Days 1-28 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Trial: NCT03332797
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib will be administered orally, once daily, at the label-recommended dose of 125 mg on Days 1-21 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Trial: NCT03964727
Drug: Sacituzumab Govitecan-hziy
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously
Trial: NCT01889199
Drug: Flutamide
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide 125 mg orally each 28 day cycle for 6 cycles
Trial: NCT00782275
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00782275
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00068406
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01296152
Drug: depo-medroxyprogesterone acetate
RxNorm normalized name: medroxyprogesterone Injection [Depo-Provera]
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At study entry/ Day 0, participants will receive Depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
Trial: NCT02018042
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.~The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug.
Trial: NCT02353299
Drug: Silenor 6 mg
RxNorm normalized name: Silenor 6 MG Oral Tablet
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Silenor 6 mg single nighttime dose.
Trial: NCT02353299
Drug: zolpidem 10 mg
RxNorm normalized name: zolpidem 10 mg oral tablet
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg single nighttime dose
Trial: NCT01640093
Drug: Abiraterone acetate, 250 mg (coated, reformulated tablet)
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
Trial: NCT01640093
Drug: Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
Trial: NCT01778179
Drug: Tri-luma
RxNorm normalized name: Tri-Luma
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-procedure phase (From Baseline up to Week 2) treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.~Post-procedure phase (From week 2 up to Week 13 - Visit )~- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH.
Trial: NCT03823378
Drug: Elsubrutinib
RxNorm normalized name: Elsubrutinib
DrugBank: Elsubrutinib (DB18850)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elsubrutinib capsule will be administered orally.
Trial: NCT03823378
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib tablet will be administered orally.
Trial: NCT03823378
Drug: Placebo for elsubrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule for elsubrutinib will be administered orally.
Trial: NCT03823378
Drug: Placebo for upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib placebo tablet will be administered orally.
Trial: NCT00058539
Drug: rhuMAb 2C4 (pertuzumab)
RxNorm normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no